Live price temporarily unavailable.
Organon & (OGN) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $7.78B | $6.53B | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Growth (year over year) | — | −16.0% | −3.5% | −2.1% | +1.4% | +2.2% | −2.9% |
| Gross profit | $5.50B | $4.41B | $3.92B | $3.88B | $3.75B | $3.71B | $3.31B |
| Gross margin | 70.8% | 67.6% | 62.2% | 62.8% | 59.8% | 58.0% | 53.3% |
| Net income | $3.22B | $2.16B | $1.35B | $917.0M | $1.02B | $864.0M | $187.0M |
| Net margin | 41.4% | 33.1% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| EPS (diluted) | $12.69 | $8.52 | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Balance sheet | |||||||
| Cash and equivalents | $0 | $12.0M | $737.0M | $706.0M | $693.0M | $675.0M | $574.0M |
| Total assets | — | $10.1B | $10.7B | $11.0B | $12.1B | $13.1B | $12.9B |
| Total liabilities | — | $4.62B | $12.2B | $11.8B | $12.1B | $12.6B | $12.1B |
| Long-term debt | — | $0 | $9.13B | $8.90B | $8.75B | $8.86B | $8.63B |
| Shareholders' equity | $7.04B | $5.49B | −$1.51B | −$892.0M | −$70.0M | $472.0M | $752.0M |
| Cash flow | |||||||
| Operating cash flow | $3.02B | $2.28B | $2.16B | $858.0M | $799.0M | $939.0M | $700.0M |
| Capital expenditure | $92.0M | $255.0M | $192.0M | $196.0M | $251.0M | $175.0M | $162.0M |
| Free cash flow | $2.93B | $2.03B | $1.97B | $662.0M | $548.0M | $764.0M | $538.0M |
| Dividends paid | $0 | $0 | $145.0M | $290.0M | $294.0M | $297.0M | $88.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.58B | $1.59B | $1.51B | $1.59B | $1.60B | $1.51B | $1.46B | $1.56B |
| Growth (year over year) | +4.1% | −0.4% | −6.7% | −0.8% | +1.3% | −5.3% | −3.5% | −2.3% |
| Gross profit | $923.0M | $896.0M | $841.0M | $874.0M | $857.0M | $741.0M | $783.0M | $847.0M |
| Gross margin | 58.3% | 56.3% | 55.6% | 54.8% | 53.5% | 49.2% | 53.6% | 54.4% |
| Net income | $359.0M | $109.0M | $87.0M | $145.0M | $160.0M | −$205.0M | $146.0M | $108.0M |
| Net margin | 22.7% | 6.8% | 5.8% | 9.1% | 10.0% | −13.6% | 10.0% | 6.9% |
| EPS (diluted) | $1.38 | $0.42 | $0.33 | $0.56 | $0.61 | −$0.78 | $0.55 | $0.40 |
| Balance sheet | ||||||||
| Cash and equivalents | $763.0M | $675.0M | $547.0M | $599.0M | $672.0M | $574.0M | $1.12B | $1.13B |
| Total assets | $12.8B | $13.1B | $13.2B | $13.5B | $13.6B | $12.9B | $13.0B | $13.2B |
| Total liabilities | $12.3B | $12.6B | $12.6B | $12.8B | $12.6B | $12.1B | $12.1B | $12.2B |
| Long-term debt | $8.74B | $8.86B | $8.94B | $8.78B | $8.78B | $8.63B | $8.55B | $8.48B |
| Shareholders' equity | $493.0M | $472.0M | $542.0M | $733.0M | $906.0M | $752.0M | $903.0M | $1.01B |
| Cash flow | ||||||||
| Operating cash flow | $141.0M | $390.0M | $75.0M | $220.0M | $264.0M | $141.0M | $225.0M | $107.0M |
| Capital expenditure | $42.0M | $55.0M | $32.0M | $39.0M | $46.0M | $45.0M | $37.0M | $42.0M |
| Free cash flow | $99.0M | $335.0M | $43.0M | $181.0M | $218.0M | $96.0M | $188.0M | $65.0M |
| Dividends paid | $74.0M | $74.0M | $71.0M | $10.0M | $3.00M | $4.00M | $5.00M | $6.00M |
From Organon &'s 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Organon & in our feed yet.